We wish to congratulate ImmuneWorks, Inc., a long-time client of Milestone Advisors, on the announcement of its Development Agreement with Lung Rx, a wholly-owned subsidiary of United Therapeutics Corporation, to pursue development of ImmuneWorks' lead compound (IW001) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, usually fatal disease that afflicts in excess of 100,000 persons in the United States alone.
Founded in 2006, ImmuneWorks, Inc. is a biotechnology company committed to developing safe and effective immune tolerance treatments for patients with serious autoimmune diseases. Milestone Advisors has had the privilege of providing Part-Time CFO and Part-Time Controller services to ImmuneWorks. Congrats!
Click here to see the full story.
Founded in 2006, ImmuneWorks, Inc. is a biotechnology company committed to developing safe and effective immune tolerance treatments for patients with serious autoimmune diseases. Milestone Advisors has had the privilege of providing Part-Time CFO and Part-Time Controller services to ImmuneWorks. Congrats!
Click here to see the full story.
Powered by Compendium Blogware
Comments for Congratulations To ImmuneWorks